SAN ANTONIO -- More than 70% of patients with advanced triple-negative breast cancer (TNBC) responded to an investigational bispecific antibody targeting PD-L1 and VEGF-A plus chemotherapy, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results